Please try another search
Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company’s products include recombinant human interferon alfa-2b injection; vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; and compound glycyrrhizin. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Ke Wu | 31 | 2021 | Chairman of Supervisory Board |
Manli Sun | 52 | 2021 | Independent Director |
Jianwei Zhu | 66 | 2021 | Independent Director |
Junfeng Wang | 48 | 2021 | Director |
Wang Peng | 41 | 2021 | Director |
Desheng Zhou | 51 | 2008 | General Manager and Chairman of the Board |
Runlu Deng | 62 | 2008 | Director |
Rong Li | 38 | 2021 | Supervisor |
Chen Du | 63 | 2021 | Independent Director |
Chenghao Zhu | 47 | 2021 | Supervisor |
Jifeng Shi | 50 | 2017 | Deputy General Manager and Director |
Chongfei He | 55 | 2008 | Deputy GM, Secretary & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review